Miltefosine is an important drug for the treatment of leishmaniasis; however, its mechanism of action is still poorly understood. In these studies, we tested the hypothesis that like in cancer cells, miltefosine's efficacy in leishmaniasis is due to its inhibition of Akt activation in host cells. We show using pharmacologic agents that block Akt activation by different mechanisms and also using an inducible knockdown approach that miltefosine loses its efficacy when its access to Akt1 is limited. Interestingly, limitation of Akt activation results in clearance of established Leishmania infections. We then show, using fluorophore-tagged probes that bind to phosphoinositides, that Leishmania parasitophorous vacuole membranes (LPVMs) display the relevant phosphoinositides to which Akt can be recruited and activated continuously. Taken together, we propose that the acquisition of PI(4) P and the display of PI (3,4)P2 on LPVMs initiate the machinery that supports continuous Akt activation and sensitivity to miltefosine.
alkylphospholipids including perifosine were shown to act by disrupting PI3K/Akt signalling in cancer cells (Chakrabandhu, Huault, & Hueber, 2008; Jangir et al., 2014; van Blitterswijk & Verheij, 2013) . More recently, miltefosine was repurposed for the treatment of leishmaniasis (Croft & Engel, 2006) . Miltefosine is now the indicated drug for the treatment of visceral leishmaniasis (McGwire & Satoskar, 2014) . It is also indicated for the treatment of cutaneous leishmaniasis; however, its efficacy for treating cutaneous Leishmania infections is variable (del Mar Castro et al., 2017; Fernández et al., 2014) . The basis for the variable sensitivity of some Leishmanias to miltefosine is not understood.
Moreover, there is concern for the potential appearance and spread of parasites that are resistant to miltefosine (Bhandari et al., 2012; Ostyn et al., 2014) . Since the adoption of miltefosine for treatment of leishmaniasis, several studies have investigated miltefosine's mechanism of action in Leishmania infections. Most of those studies have focused on the direct effects of miltefosine on the parasite; these studies have shown that miltefosine affects lipid metabolism in the parasite, induces mitochondrial dysfunction, and induces apoptosis of amastigotes (Santa-Rita, Henriques-Pons, Barbosa, & de Castro, 2004 , Paris, Loiseau, Bories, & Bréard, 2004 , Luque-Ortega & Rivas, 2007 , Turner et al., 2015 . Although some of these observations are controversial, together, they suggest that miltefosine may have several targets in the parasite that could explain why parasite species and strains differ in their susceptibility to the drug. It has also been proposed that miltefosine's mechanism of action in Leishmania infections may be through its targeting of host processes including Akt-mediated signalling (Dorlo, Balasegaram, Beijnen, & de Vries, 2012; Seifert, Escobar, & Croft, 2010) In this study, we initially show that miltefosine is effective at lower concentrations against intracellular parasites as compared with extracellular parasites, which suggests that the targeting of a host cell component mediates the action of miltefosine against Leishmania parasites at low miltefosine concentrations. Those studies reveal that limitation of Akt activation reduces Leishmania survival in macrophages in the absence of additional stimuli, which implies that modulation of Akt activation is a viable strategy for controlling Leishmania infections. We then show that blocking Akt availability or its activation results in reduced efficacy of miltefosine. We tracked the distribution of the relevant phosphoinositides that are required for Akt activation, in order to gain insight on the intracellular sites in infected cells that can support continuous Akt activation. Specifically, using fluorophore-tagged lipid-binding probes that bind to PI (3,4)P2 or PI (3,4,5)P3 and their precursors, we show that Leishmania parasitophorous vacuole membranes (LPVM) display PI (3,4)P2 to which Akt can bind and be activated. LPVMs also display PI(4) P, which is an important precursor of PI (3,4)P2.
| RESULTS

| Miltefosine has direct effects on Leishmania parasites
Leishmania spp. exhibit differences in their sensitivity to miltefosine (del Mar Castro et al., 2017; Paris et al., 2004) . To commence our studies, we tested the efficacy of miltefosine on two parasite lines that Several studies have reported that Leishmania amastigote forms within macrophages are more sensitive to miltefosine as compared with promastigotes in axenic culture (Dorlo et al., 2012; Escobar, Matu, Marques, & Croft, 2002; Seifert et al., 2010) . We proceeded therefore to evaluate the sensitivity of the L. donovani and L. amazonensis parasites lines to miltefosine after infections of RAW264.7 mouse macrophages. It had previously been reported that at concentrations above 20 μM, miltefosine is increasingly toxic to macrophages; specifically, on J774, a mouse macrophage-like cell line, miltefosine toxicity was estimated at IC 50' s of 24 to 26 μM (Azzouz, Maache, Garcia, & Osuna, 2005) . To ensure that we evaluate the effects of miltefosine on Leishmania infections at concentrations that are not toxic to macrophages, we limited evaluations of miltefosine to maximum concentrations of 10-15 μM. At those concentrations, which result in clearance of approximately 90% of parasites from within macrophages, miltefosine is not toxic to RAW264.7 cells ( Figure S1a ).
The efficacy of miltefosine on intracellular parasites after 24-hr infections was estimated by microscopy after Giemsa staining. Survival curves were generated (Figure 1b) . The estimated EC 50 for miltefosine on L. donovani infections was 6 μM+/−0.56 μM, and for L. amazonensis, the EC 50 of miltefosine was estimated at 6+/−1.03 μM. Infections were also performed on peritoneal exudate cells that were obtained 4 days after intraperitoneal injection of thioglycolate into BALB/c mice. The EC 50 of miltefosine on L. amazonensis-infected peritoneal exudate cells was 6.16+/−1.86 μM. These observations show that in the laboratorymaintained parasite lines as well, intracellular amastigotes are more sensitive to miltefosine as compared with the extracellular promastigote forms. In addition, these results show that sensitivity of parasites to miltefosine in the RAW264.7 macrophage cell line was comparable with sensitivity in primary macrophages. The observations above are in agreement with several published studies that have reported that Leishmania species (and isolates) exhibit differences in sensitivity to miltefosine and that intracellular parasites are more sensitive than extracellular parasites to miltefosine (Coelho, Trinconi, Costa, & Uliana, 2014; Seifert et al., 2010) . On the basis of those observations, we hypothesised that the increased efficacy of miltefosine on intracellular parasites is mediated by its effects on a host target of the drug. In light of studies on the mechanism of action of miltefosine on cancer cells that implicated Akt as its primary target, the subsequent studies presented below were designed to evaluate Akt as the target of miltefosine in Leishmania-infected host cells.
| Akt activation is sustained in Leishmaniainfected cells
To commence the evaluation of Akt activation in infected cells, we evaluated the time course of Akt activation in macrophages after infection with Leishmania parasites. Macrophages incubated with L. donovani or L. amazonensis parasites showed an increase in both the T308 and S473 pAkt forms within 15 min that peaked at 30 min ( Figure 2a) . A second activation phase was sustained through 72-hr post infection. Glycogen synthase kinase 3(GSK3β) is a downstream substrate of Akt, whose phosphorylation can be assessed as a functional readout of Akt activation (Manning & Toker, 2017) .
Leishmania infection resulted in sustained phosphorylation of GSK3β (Figure 2a) . Akt activation in Leishmania-infected cells is apparently biphasic, which is highlighted by the line plot through the compiled densitometry data from western blot experiments (Figure 2a ). These results are in agreement with observations by Ruhland, Leal, and Kima (2007) , but those studies evaluated other parasite species and a shorter time course. In typical infection experiments of RAW264.7 macrophages over a 72-hr time course, there is an increase in the number of parasites per macrophage (Figure 2b ). It is known that the uptake of Zymosan particles by macrophages is mediated by phagocytic receptors, the ligation of which activates PI3K signalling that leads to the phosphorylation of Akt (Tamura et al., 2009) . We observed that peak activation of Akt in macrophages in response to Zymosan was after 15-min incubation (Figure 2 ). pAkt levels returned to resting levels once the particles were internalised and the events at the PM dissipated. Similarly, after a quick increase, pGSK3β levels also returned to resting stage levels in macrophages harbouring Zymosan particles (Figure 2 ). Taken together, these results show that in contrast to Leishmania infection, the uptake of Zymosan particles does not result in the biphasic increase in pAkt levels. The second wave of Akt activation in Leishmania-infected cells is evidently distinct from classical phagocytosis, suggesting the possible development of a new intracellular site from which Akt activation is sustained.
| Miltefosine blocks Akt activation
In tumour cells, miltefosine was shown to block Akt activation (Chakrabandhu et al., 2008 , Jangir et al., 2014 . In light of those studies, we sought to confirm that miltefosine blocks Akt activation in macrophages in response to hormonal activation and also in response to Leishmania infection. For assessment of hormonal activation, macrophages were pre-incubated with miltefosine or medium alone (control) prior to their incubation with insulin, which is a potent activator of FIGURE 1 Miltefosine is effective on extracellular Leishmania and also on intracellular Leishmania in infected macrophages. (a) The efficacy of miltefosine on promastigote forms of Leishmania was measured in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Parasites were incubated with increasing concentrations of miltefosine. Proportion of surviving parasites was analysed by GraphPad prism, and the EC 50 was calculated from those plots. (b) RAW264.7 macrophages were infected with either Leishmania amazonensis or Leishmania donovani promastigotes. After 24 hr, infections were treated with indicated concentrations of miltefosine and infected cells fixed after an additional 24 hr. After Geimsa staining, infected cells were enumerated. The data are presented as the relative infection rate. (c) The data from the miltefosine treatment experiments were also scored as the number of parasites per 100 cells. The data presented in this figure were from at least four experiments that were compiled and plotted in GraphPad FIGURE 3 Miltefosine inhibits Akt activation after hormonal treatment and also after Leishmania infection. (a) Macrophages were pre-incubated with miltefosine or medium (con) before co-incubation with Insulin. After 15 min, cell lysates were prepared and analysed in western blots. Blots were probed for T308 and S473 pAkt forms. The pAkt band densities were determined and normalised to band densities in control treated cells. The data were compiled in GraphPad. Determination of statistical significant difference between with or without miltefosine treatment was by Student's t test. (b) For Leishmania infections, macrophages were infected with Leishmania amazonensis for 24 hr. Then miltefosine or vehicle was added and incubated for an additional 24 hr. Lysates were prepared and analysed in western blots for T308 and S473 pAkt forms. The pAkt band densities were determined and normalised to band densities in control treated cells. The data were compiled in GraphPad. Determination of statistical significant difference between with or without miltefosine treatment was by Student's t test FIGURE 2 Akt is activated continuously in Leishmania infections. (a) After incubation of macrophages with Leishmania parasites or serumopsonized Zymosan particles, lysates were prepared at indicated times, and equivalent amounts of protein from each lysate was processed for western blot analysis. Blots were initially probed with antibodies to T308 or with antibodies to S473. Most blots were stripped and probed for total Akt. Western blots with equal amounts of those lysates were also probed for GSK-3β. Density of bands from at least four experiments was compiled. The density of bands for each experiment was normalised to the band density in resting cells. These data were compiled in GraphPad, which is where plots were generated in GraphPad. The activation of Akt in Leishmania infections is biphasic. A line plot generated from the data was overlaid to highlight the activation pattern of Akt. (b) The progress of infections in infected cells is routinely measured. Coverslips recovered after each infection are stained with Giemsa. Then the number of parasites per infected macrophage is enumerated. The plot is of the mean number of parasites per macrophage from at least four experiments Akt (Liang, Han, Senokuchi, & Tall, 2007) . As shown in Figure 3a 
| Miltefosine is less effective against Leishmania after Akt knockdown
There is increasing evidence that the three isoforms of Akt have distinguishable functions (Toker & Marmiroli, 2014) . We had found previously that the knockdown of Akt1 was sufficient to render Leishmania-infected cells susceptible to apoptosis inducers (Ruhland et al., 2007) . Caradonna, Engel, Jacobi, Lee, and Burleigh (2013) We proceeded to infect the Akt1 shRNA-2 line with L. donovani parasites. After 12-hr infection, doxycycline was added to the infection cultures to induce shRNA synthesis. After 24 hr, miltefosine FIGURE 4 Inducible knockdown of Akt1 reduces Leishmania viability in infected cells and also reduces miltefosine efficacy. The RAW264.7 macrophage line was transduced with recombinant lentiviruses expressing one of three shAkt1 sequences (materials and methods) and selected by growth in puromycin. The line with the shAkt1-2 sequence was incubated with doxycycline after which lysates were prepared at indicated times. (a) Western blots were probed with anti-Akt1 or actin. A control mCMV cell line was analysed in parallel experiments. Densitometric scans of bands from several experiments were compiled and plotted in GraphPad. (b) Wild-type cells and the shAkt1-2 line were infected with Leishmania donovani, and infections were scored after 48 hr. (c) Infections were scored after incubation with or without doxycycline to induce Akt1 knockdown. (d) Infections were incubated with doxycycline and then co-incubated with increasing concentrations of miltefosine. Infections with co-incubation in miltefosine were normalised with infections with doxycycline. Survival curves from at least three experiments were compiled and curves plotted GraphPad 7. Statistical significance between treated infected cells and the control was measured using a one-way analysis of variance with the Dunnett's test for multiple comparisons or vehicle was added to the cultures. The cultures were incubated for an additional 24 hr after which they were fixed and evaluated after Geimsa staining. Figure 4b shows that there was no effect on parasite 
| Evaluations of Akt as the target of miltefosine in macrophage infections
For another approach to evaluate the hypothesis that Akt is the primary target of miltefosine in Leishmania infections, the effect of pharmacological inhibitors was evaluated. We showed earlier that incubation of cells with miltefosine results in the inhibition of Akt phosphorylation ( Figure 3) . However, the mechanism by which miltefosine disrupts Akt activation is still not well understood. A report by showed that miltefosine most likely blocks Akt activation by interfering with the binding of Akt's pleckstrin homology domain to PI (3,4) P2 or PI (3,4,5)P3. PDK1, which phosphorylates Akt at T308, also binds to these phosphoinositides. We reasoned that if miltefosine's action was directed at Akt, then incubation of miltefosine with co-inhibition of PKD1 or other inhibitors of Akt would alter the efficacy of miltefosine.
PDK1 inhibitor II inhibits the phosphorylation of Akt at T308 by PDK1 (Islam et al., 2007) . At the concentrations and incubation conditions evaluated in these experiments, the PDK1 inhibitor II is not toxic to macrophages ( Figure S1b ). First, western blots were performed to evaluate the effect of PDK1 inhibitor II on Akt phosphorylation (Figure 5a ). On average, 40% and 60% inhibition of Akt phosphorylation were achieved at 24 and 48 hr, respectively. Then, prior to adding miltefosine, incubation of infected cells with the PDK1 II inhibitor resulted in a 30% reduction in L. donovani-infected cells (Figure 5b) and a 24% reduction in the number of L. amazonensis-infected cells ( Figure S3a) . The reduction in the number of infected cells was statistically significant. This result is consistent with previous observations that showed that reduced Akt activation limits Leishmania parasite survival in macrophages. We proceeded to assess the killing efficacy of miltefosine on parasites in infected macrophages while actively inhibiting Akt activation with the PDK1 II inhibitor. In light of the fact that PDK1 inhibitor II treatment alone results in reduced infection levels, the infections with co-incubation of PDK1 inhibitor II and miltefosine were normalised so that any additional effects resulting from miltefosine treatment would be apparent. In infection cultures to which dimethylsulfoxide (DMSO) but no PDK1 inhibitor II was added, the EC 50 of miltefosine on L. donovani infec- inhibitor II. Akt inhibitor IV and Akt inhibitor VIII (Calbiochem) that exert direct effects on all three Akt isoforms or two Akt isoforms, respectively, were tested. In addition, inhibitors of the mammalian target of rapamycin (mTOR) were also tested. The two mTOR complexes, mTORC1 and mTORC2, are downstream kinases in the PI3K/Akt signalling pathway (Saxton & Sabatini, 2017) . mTORC2 has been identified as one among other kinases that can phosphorylate Akt at S473. Most commercially available pharmacological inhibitors of mTOR inhibit both mTORC1 and mTORC2. For the studies here, we evaluated the effects of the mTOR inhibitor XI Torin 1 (Torin 1). The toxicity of each of these inhibitors to RAW264.7 macrophages was evaluated at the concentration and incubation times in these experiments ( Figure S1a ). Only AktIV inhibitor was found to be toxic to macrophages. Consequently, it was not used in subsequent experiments.
Co-incubation with each of these Akt inhibitors reduced the efficacy of miltefosine on Leishmania infections. The results of those studies are shown in Figure S3b .
Other signalling molecules such as the MAP kinases and molecules in the toll-like receptor pathway have been implicated in the survival of Leishmania within macrophages (Martinez & Petersen, 2014; Terrazas et al., 2015) . To determine whether inhibition of MAP kinase or toll-like receptor pathways has a comparable effect on the efficacy of miltefosine, we assessed the effect of inhibition of those signalling pathways on the efficacy of miltefosine. Inhibition of MAP kinase p38 was accomplished with SB202190 (evaluated previously in Leishmania infections, Ruhland et al., 2007) . Toll-like receptor 4 (TLR4)-dependent signalling was inhibited with CLI-095, which also inhibits ERK and JNK map kinase (Lee et al., 2016) . As shown in Figure 5c , neither CLI-095 nor SP202190 resulted in reduced levels of Akt phosphorylation. Unlike the inhibitors of Akt, incubation with CLI-095 and SP202190 did not change the rate of established infections. Moreover, co-incubation with these inhibitors did not alter the efficacy of miltefosine. The EC 50 of miltefosine after co-incubation with SB202190 or CLI-095 were 7.38+/−2.67 and 6.91+/−3.31 μM, respectively (Figure 5d ). Together, the results of these experiments show that inhibition of Akt activation alters the efficacy of miltefosine, whereas inhibition of other signalling pathways that have also been shown to be activated during Leishmania infection does not alter the efficacy of miltefosine.
| Killing of intracellular Leishmania by miltefosine is mediated by reactive oxygen species (ROS)
Several studies have described a cross-talk between the induction of ROS and Akt activation (reviewed by Zhang et al., 2016) . Studies on the alkylphospholipds have also shown a link between their actions and activation of ROS (Canuto et al., 2014; Shen, Hong, Zhao, & Zhang, 2016) . In light of the observations reported above that showed that miltefosine efficacy was dependent on Akt availability, we assessed the impact of blocking ROS on miltefosine's efficacy. Infected macrophages were incubated with N-acetyl-L-cysteine (NALC), an inhibitor of ROS, with or without co-incubation with miltefosine. When L. donovani infections were incubated with NALC alone, it had no effect on the course of Leishmania infection (Figure 6a ). However, when miltefosine was co-incubated with NALC, the efficacy of miltefosine (Canuto et al., 2014) . Together, these FIGURE 5 Inhibition of PDK1 reduces miltefosine efficacy. PDK1 inhibitor II was added to 12-hr-old infected cells. In parallel cultures, miltefosine at 5 μM was co-incubated with the PDK1 inhibitor II on infected cells. Lysates were prepared after an additional 24 or 48 hr. (a) Western blot of the samples was probed with antibodies to T308 followed after stripping with a pan Akt antibody. Densitometric scans of bands from at least four experiments were compiled. (b) Proportion of Leishmania donovani-infected cells was estimated in cultures without or with addition of PDK1 inhibitor II addition; L. donovani-infected cells were estimated in cultures with dimethylsulfoxide or with PDK1 inhibitor II and co-incubation with increasing concentrations of miltefosine. Infections were normalised to the maximum infection rates that were obtained after PDK1 inhibitor II treatment. Data from at least four repetitions was compiled analysed in GraphPad Prism 7, where graphs were generated. The EC 50 of miltefosine under these conditions was estimated from the data used to generate these curves. Significance of difference was determined by multiple t tests. (Key: NI is noninfected resting cells; I is infected cells at 24 hr; PII (24) or (48) is "how is Akt activation sustained in Leishmania-infected cells?" A critical and rate-limiting step in the activation scheme of Akt is the presence on the PM of PI (3,4)P2 or PI (3,4,5)P3, to which Akt is recruited (Manning & Cantley, 2007) . In light of the critical role of these phosphoinositides, we proceeded to determine whether the LPVM is an internal site within infected cells where these lipids are displayed and to which Akt could be recruited and activated. The pleckstrin homology domain probe, PH-Akt (GFP), is a well-characterized probe for evaluating the distribution of PI (3,4)P2 and PI (3,4,5)P3 (Balla & Várnai, 2002; Balla & Várnai, 2009) . To determine the distribution of these phosphoinositides in infected macrophages, PH-Akt (GFP) was transiently expressed in RAW264.7 macrophages, which were then infected with either L. donovani or L. amazonensis parasites. Infections were evaluated at 2-and 24-hr post infection. At 2 hr, it is expected that most events associated with parasite entry would have dissipated. At 24-hr post infection, Leishmania promastigote forms that initiated the infection in macrophages should have fully transformed into amastigote forms, and parasite replication should have commenced (Doyle, Engel, Gam, & Dvorak, 1989) . (Ndjamen et al., 2010) . We interpret this observation to imply that LAMP-1 is delivered to LPVs via a mechanism that is distinct from the mechanism by which the lipid precursors of PI (3,4)P2 and PI (3,4,5)P3 are delivered to LPVs.
To determine whether the display of PI (3,4)P2 and PI (3,4,5)P3 on a phagosome-like compartment is restricted to LPVs, cells expressing PHAkt (GFP) were allowed to internalise Zymosan particles, and the distribution of the lipid reporter on Zymosan-containing phagosomes (ZCP) was monitored as well. Although Zymosan particles were found within LAMP-1 positive phagosomes, these ZCPs were for the most part not labelled with the PH-Akt (GFP) at the indicated times (Figure 7b ). Less than 20% of ZCPs were reactive with the PH-Akt (GFP) probe (Figure 8 c), which is at the false-positive threshold estimated with the PH-Akt (R25C)(GFP) mutant probe. Nigorikawa et al. (2015) using Zymosan particles and Bohdanowicz, Cosío, Backer, & Grinstein, (2010) using opsonized red blood cells had shown that after internalisation of those particles by RAW 264.7 macrophages, PI (3,4,5)P3 and also PI (3,4)P2 are lost from nascent phagosomes soon after internalisation. Our observations that these phosphoinositides displayed on 2-and 24-hr-old LPVs underscore the differences between LPVs and classical phagosomes.
FIGURE 6
Inhibition of ROS reduces efficacy of miltefosine. Leishmania donovani-infected cells were incubated with 2-nM N-acetyl-L-cysteine (NALC) or with dimethylsulfoxide (diluent). The number of infected cells after 24 hr was enumerated (a). The killing efficacy of increasing concentrations of miltefosine co-incubated with NALC was determined (b). Data was compiled and plotted in GraphPad. The EC 50 of miltefosine was determined from these curves. The results were compiled from three experiments 2.9 | Phosphoinositide precursor of PI (3,4)P2 but not the precursor of PI (3,4,5) is displayed on LPVMs
The PH-Akt (GFP) probe is reactive to both PI (3,4)P2 and PI (3,4,5)P3 lipids (Manning & Cantley, 2007) . These lipids have distinct biosynthetic and metabolic schemes (De Craene, Bertazzi, Bär, & Friant, 2017) . To gain more insight into which of these phosphoinositides is displayed on LPVMs, we sought to determine whether the precursor lipids for PI (3,4)P2 and PI (3,4,5)P3 are also displayed on LPVs. Several studies have shown that PI (4,5) P, which is abundant on the PM is the ; not shown). Based on these results, our interpretation is that PI (4,5) P is not displayed on the LPVM. PI (4,5) P is therefore unlikely to be the precursor of the phosphoinositide species on LPVMs to which the PH-Akt (GFP) probe is reactive. We did not rule out the possibility that the absence or limited presence of PI (4,5) P could be explained by the unsuitability of this probe to detect this lipid in non-PMs; however, Botelho et al. (2000) showed that this lipid is barely detected on nascent phagosomes after sealing of the phagocytic cup.
PI(4) P can be converted to PI (3,4)P2 by Class II PI3kinases (Hawkins & Stephens, 2016) . PI(4) P is an abundant lipid in secretory pathway compartments including the ER and the Golgi (Graham & Burd, 2011 , Mesmin et al., 2013 . To determine whether PI(4) P is displayed on LPVMs, we evaluated the distribution of the Legionella pneumophila PtdIns4P-interacting effector SidM Legionella (sidM-GFP; Hammond, Machner, & Balla, 2014) in Leishmania-infected cells. Hammond et al. (2014) showed that the sidM-GFP is a reliable probe for PI(4) P. Our initial studies with sidM-GFP yielded poorly expressing RAW264.7 macrophages. Better expressing cells and unambiguous results were obtained with the GFP-P4M-SidMx2, which consists of two P4M binding domains fused in tandem and tagged with GFP (Hammond et al., 2014) . Although in the initial description of this probe that GFP-P4M-SidMx2 was believed to cause distressed Golgi, a subsequent study by Levin et al. (2017) found this probe to function adequately in RAW264.7 cells that expressed low-to-moderate levels of this probe. We first assessed the distribution of the GFP-P4M- Rabouille and Linstedt, (2016) or LAMP-1. We observed that GFP-P4M-SidMx2 colocalizes exquisitely with Grasp65. Hammond and colleagues (2014) showed that GFP-P4M-SidMx2 labelled a subset of late endocytic compartments as well. In our studies, we also found that some GFP-P4M-SidMx2-positive vesicles were also LAMP-1-positive. Upon infection with Leishmania parasites, the GFP-P4M-SidMx2 was abundantly recruited to LPVs. Figure 8b shows representative images of L. amazonensis and L. donovani LPVs at 2-and at 24-hr post infection.
The LPVM is conspicuously labelled by the GFP-P4M-SidMx2 probe.
The white arrow in the GFP-P4M-SidMx2 expressing cells points to positively labelled LPVs. The GFP-P4M-SidMx2 probe also labels the Golgi, which are counterstained for Grasp65. At 2-hr post infection greater than 80% of infected cells have at least one LPV that is reactive with the GFP-P4M-SidMx2 probe (Figure 8d ). There was a statistically insignificant decrease in the number of infected cells with at least one GFP-P4M-SidMx2-positive LPV at 24-hr post infection.
Comparable observations were made with L. donovani-infected cells.
To assess the specificity of this recruitment, GFP-P4M-SidMx2-transfected cells that internalised Zymosan particles were evaluated.
Representative images are shown in Figure 8c . Some ZCPs were conspicuously labelled with GFP-P4M-SidMx2 probe. The white arrow points to a labelled ZCP. We enumerated the number of cells with at least one positively labelled ZCP. The result in Figure 8d shows that at 24 hr, approximately 60% of cells that took up Zymosan particles had at least one ZCP that was reactive with the GFP-P4M-SidMx2 probe. Although there is a significant pool of PI(4) P in the Golgi, this probe also detects PI(4) P pools in endocytic pathway compartments, which are the most likely source of PI(4) P on ZCPs. Taken together, the results above show that PI (4,5)P2, which is the immediate precursor for PI (3,4,5)P3, is absent from LPVs. In contrast, PI(4) P, which is the immediate precursor for PI (3,4)P2, is displayed on LPVs in most infected cells.
| LPVs display PI (3,4)P2
As discussed above, the PH-Akt (GFP) probe binds equally well to PI (3,4)P2 and PI (3,4,5)P3 (Hawkins & Stephens, 2016) . In light of the observation that PI (4,5) P, the immediate precursor of PI (3,4,5)P3, is not displayed on LPVs, it opened the possibility that it is PI (3,4)P2
and not PI (3,4,5)P3 that accounts for the reactivity of the PH-Akt (GFP) probe on LPVs. To investigate this issue further, the labelling of LPVs with Bruton's tyrosine kinase (Btk-PH-GFP), a more specific Turner et al., 2015) . Most of the direct effects on parasites occur at miltefosine concentrations greater than 25 μM, which are concentrations at which miltefosine toxicity to macrophages has been reported (Azzouz et al., 2005) . However, the efficacy of miltefosine on Leishmania-infected cells has been shown to be as low as 2 μM, which is consistent with observations reported in this manuscript. There are at least three major explanations for why distinct concentrations of miltefosine are effective on extracellular organisms as compared with intracellular parasites in infected cells:
(a) The intracellular amastigotes express novel activities that are more FIGURE 9 Btk-PH-GFP exhibits limited reactivity with Leishmania parasitophorous vacuoles (LPVs). Representative images show the distribution of the Btk-PH-GFP probe and of LAMP1 in RAW264.7 cells that were transfected with the Btk-PH-GFP probe and infected with either Leishmania donovani or Leishmania amazonensis parasites. Images are Zprojections at average intensities of deconvolved Z-series sections. Reactivity with DAPI was also included. White arrows point to representative LPVs and the parasites within them. We enumerated the number of Btk-PH-GFP transfected cells and infected with L. donovani with at least one positive LPV. Cells transfected with the PH-Btk (R28C)-GFP a non PI (3,4,5)P3 binding mutant of PH-Btk were also infected, and cells with at least one positively labelled LPV were enumerated. A plot generated in GraphPad is shown sensitive to miltefosine, (b) miltefosine preferentially accumulates in LPVs, which results in higher intravacuolar concentrations that are comparable with levels to which extracellular parasites are sensitive, and (c) miltefosine primarily targets host cell molecules or processes in infected cells that are critical for the intracellular survival of the parasite. In light of previous studies on cancer cells that showed that inhibition of Akt activation is the primary target of miltefosine and other alkylphospholipids, we evaluated the possibility that in Leishmania infections as well, miltefosine acts primarily by targeting host Akt activation at concentrations that are much lower than is required to kill axenic parasites.
Several studies had observed that the PI3K/Akt signalling pathway is activated in Leishmania infections and that inhibition of this pathway has a negative impact on the course of Leishmania infections (reviewed by Kima, 2016) . In the current studies, we evaluated tetracycline inducible Akt1 shRNA cell lines that could be induced to knockdown Akt1 levels. We showed that in established macrophage infections with either L. donovani or L. amazonensis, knockdown of Akt1 levels by greater than 50% upon addition of doxycycline resulted in greater than 50% reduction in the number of infected cells. Under Those studies found that addition of miltefosine to cultures induced ROS (Das, Pandey, Rabidas, Mandal, & Das, 2013) . Together, these studies imply that although infection does not induce significant ROS, miltefosine treatment induces elevated ROS production, which contributes in the killing of Leishmania parasites.
Although the likelihood that Akt is the primary target of miltefosine in Leishmania infections has been proposed previously (Dorlo et al., 2012) , we are not aware of any study that has investigated this possibility experimentally. An early event that is the ratelimiting step in Akt activation is the availability on the PM of PI (3,4) P2 or PI (3,4,5)P3. Both of these phosphoinositides are displayed transiently on the PM during the phagocytic uptake of particles (Bohdanowicz et al., 2010; Nigorikawa et al., 2015) . Using phosphoinositide probes that bind to PI (3,4)P2 and/or PI (3,4,5)P3, we showed that these lipids are displayed on the LPVM. In light of the strong reactivity of the PH-Akt (GFP) probe that binds to both PI (3,4)P2 and PI (3,4,5)P3, we concluded that PI (3,4)P2 is most likely the predominant phosphoinositide that is displayed on LPVMs. This conclusion is supported by the observation that the precursor of PI (3,4) P, PI(4) P, is detected on LPVs observed by the reactivity of GFP-P4M-SidMx2 probe. In contrast the precursor of PI (3,4,5)P3, PI (4,5)P2 is not detected on LPVs. Several schemes for the biogenesis of PI (3,4)P2 have been proposed. First, dephosphorylation of PI (3,4,5)P3 by SH2-containing inositol polyphosphate 5-phosphatase can lead to the production of PI (3,4)P2 (Li & Marshall, 2015) . In light of the fact that PI (3,4,5)P3 does not appear to be abundant on the LPVM, it is unlikely that PI (3,4)P2 is generated by this scheme.
Second, PI(3) P can be phosphorylated by PIPKII to produce PI (3,4) P2 (Li & Marshall, 2015) . PI(3) P is an abundant lipid in endocytic compartments. Using the EEA1-GFP probe that binds to PI(3) P, we observed no significant labelling at the LPVs at 2-and 24-hr infection times (not shown). Moreover, in light of the fact that some LAMP-1 containing compartments also display PI3P, the absence of PI3P on LPVMs, which are LAMP1 positive, suggests that PI(3) P is unlikely to be the precursor of PI (3,4)P2 on LPVMs. Lastly, PI(4) P can be converted to PI (3,4)P2 by Class II PI3kinases (Hawkins & Stephens, 2016) . On the basis of the reactivity of the GFP-P4M-SidMx2 probe with the LPVM, we confirmed that PI(4) P is displayed on LPVs, which suggests that conversion of PI(4) P to PI (3,4)P2 is the most likely scheme for its biogenesis on LPVMs. Hammond et al. (2014) and Levin et al. (2017) have recently shown that in addition to the Golgi complex, there are other PI(4) P pools in a cell. In our studies, the precise organellar origin of PI(4) P was not determined. The surprising finding was made that ZCPs also display PI(4)P. But in contrast to LPVs, ZCPs exhibited limited reactivity to the PH-Akt (GFP) probe, which suggested that neither PI (3,4)P2 nor PI (3,4,5)P3 is displayed on ZCPs. This was interpreted to imply that PI(4) P on the limiting membranes of ZCPs is not converted to PI (3,4)P2. These observations bring to the forefront several questions that could be addressed in future studies. For example, is the class II PI3kinase that converts PI(4) P to PI (3,4)P2 a parasite-derived FIGURE 10 PH-Akt (GFP)-transfected cells are less sensitive to miltefosine. RAW264.7 macrophages were transfected with PH-Akt (GFP) or with PH-Akt (R25C)(GFP) plasmids. They were infected on coverslips with Leishmania amazonensis promastigotes for 24 hr before incubation with 10-μM miltefosine for an additional 24 hr. The coverslips were processed for fluorescence microscope evaluation by mounting on slides and DAPI stained. Infected cells that express PH-AKT (GFP) or the mutant were enumerated. Nontransfected cells were processed similarly and served as the infection control. The data from three experiments were analysed in GraphPad. Determination of statistical significant difference between with or without miltefosine treatment was by Student's t test enzyme? Also, what is the organellar origin of the PI(4) P on LPVs?
Could it be derived from the Golgi pool? Which accessory molecules are co-trafficked with PI(4) P that promote its conversion PI (3,4)P2?
In summary, we evaluated the hypothesis that miltefosine controls Leishmania infections by disrupting host Akt activation. These studies affirmed the critical role that Akt plays in the survival of Leishmania parasites in infected cells. Through several approaches, we showed that miltefosine's efficacy was dependent on the availability of Akt for activation. Relative sensitivity to miltefosine may be determined by the capacity of parasites to modulate host Akt activation. The differential capacity of parasites to activate Akt may underpin differences in parasite pathogenicity. containing 15% FBS, 0.1-mM Adenosine, 0.1-mg/ml folic acid, 2-mM glutamine, 25-mM Hepes, 1% penicillin/streptomycin, 1× BME vitamins, and 1-mg/ml sodium bicarbonate in pH 6.8.
| Macrophage culture
RAW264.7 macrophages were obtained from the American Type Culture Collection and maintain in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS and 1% penicillin/streptomycin (complete DMEM) at 37°C under 5% CO 2 atmosphere. L. amazonensisinfected macrophages were incubated in complete DMEM at 34°C under 5% CO 2 atmosphere. L. donovani-infected macrophages were incubated in complete DMEM at 37°C under 5% CO 2 atmosphere.
| Macrophage infections
These experiments were performed as described previously (Ndjamen et al., 2010) . Briefly, macrophages were plated in 100-mm Petri dishes containing sterile glass coverslips and allowed to adhere overnight in complete DMEM media at 37°C with 5% CO 2 . For infections with L. donovani, the peanut agglutination (PNA) protocol (Sacks & Melby, 2001 ) was implemented to enrich for metacyclic parasites (PNA-) from anti-rabbit immunoglobulin G from Novus Biologicals (Littleton, CO).
Membranes were then washed and incubated with secondary antibody for 1 hr at room temperature. Membranes were washed and incubated in western blot substrate (Thermo Scientific) for 2 min. Membranes were exposed on X-ray film.
| shAkt macrophage lines
Macrophage lines expressing shAkt or controls were generated by transduction of SMARTvector inducible lentiviral shRNA system (Dharmacon, Lafayette, CO). Custom-made lentiviruses that included one of three sequences, shAkt1: ATCGGAAGTCCATCGTCTC, shAkt2:
GGGACTCTCGCTGATCCAC, and shAkt3: CGTTTGTGCAGCCAGC CCT, were developed. A control lentiviral recombinant containing the sequence TGGTTTACATGTTGTGTGA was also used to generate a control cell line. Lentiviral particles prepared by Dharmacon were used to transduce RAW264.7 macrophages. After 24 hr, transduced macrophages were selected by growth in 6-μg/ml puromycin in complete DMEM at 37°C under 5% CO 2 following protocols from
Dharmacon. After at least two passages under antibiotic selection, each cell line was then assessed for Akt shRNA expression. The expression of Akt shRNA was induced by growth in 1 μM doxycycline.
| Transfections with phosphoinositide probes
The following probes GFP-P4M-SidM (Addgene plasmid #51469), Parton. Plasmids were isolated and test digested for confirmation.
They were then introduced into RAW264.7 by nucleofection using reagents from Mirus Bio (Madison, Wisconsin). After seeding transfected cells and overnight culture, they were infected. Infection of transfectants was evaluated after 2 or 24 hr.
| Determination of drug EC 50 s and promastigotes survival
To determine the EC 50 of miltefosine on axenic parasites, an MTT cell viability assay kit was used. Early stationary phase promastigotes were seeded at 1 × 10 5 parasites per well in a 96-well tissue culture plate and allowed to grow for 24 hr at room temperature in the presence of miltefosine at concentrations ranging from 0 to 100 μM. Parasite susceptibility to the DMSO vehicle alone was assessed by treating parasites at an equal concentration of DMSO to the highest concentration of drug used in each experiment. Promastigotes were incubated with MTT for 2 hr, and formazan product was read at 570-nm wavelength and a 630-nm background wavelength as described by the Biotium protocol. Viable parasites were estimated from an MTT standard curve that was made from serial dilutions of parasites and correlation of those values to the relative amount of formazan product. Plots of % Cell
Viability as compared with controls versus Log Molar Concentration were generated in GraphPad Prism 6. EC 50' s were calculated by nonlinear regression analysis of the sigmoidal curves that were generated.
Significance of the differences in parasite growth was determined using the multiple t test function. Statistical significance between time points of each concentration was measured using a Student's t test.
Immunofluorescence assays were as described in Ndjamen et al. (2010) . Briefly, labelled coverslips were examined, and images captured using a QImaging Retiga 1300C cooled CCD camera mounted on an 
| Statistical analysis of results
Data analysis and the generation of graphs were performed using Microsoft Excel and GraphPad Prism 7 (La Jolla, CA). Data are presented as the mean ± standard error. Statistical significance between time points of each concentration and also between treated-infected and treated-uninfected cells was measured using the Student's t test or one-way or two-way analysis of variance (dependent on the experimental details) in GraphPad Prism 7. This was followed by either the Holm-Sidak or the Dunnett's post hoc tests.
